|
|
News Breaks | | | | February 14, 2013 | | 14:13 EDT |  | ACT, TEVA | Actavis wins part of appeals court ruling against Teva unit
A U.S. appeals court reversed part of a ruling in favor of Watson Pharmaceuticals, now known as Actavis (ACT), over Teva's (TEVA) Cephalon unit in a patent lawsuit over the cancer drug Fendora. The appeals court upheld a lower court's ruling that a generic version made by Actavis did not copy the way the drug is delivered into the system through a mucous membrane. The appeals court did overturn a lower court ruling that the patents are invalid, however.Reference Link | |
|
News For ACT;TEVA From The Last 14 Days Check below for free stories on ACT;TEVA the last two weeks. |
|
|
| June 19, 2013 | | 08:04 EDT | | ACT | Actavis and Kissei file patent infringement lawsuits against Sandoz and Hetero
 Subscribe for More Information | | | 08:02 EDT |  | TEVA | Teva initiated with a Buy at Maxim
Subscribe for More Information | | | 07:51 EDT |  | ACT | EC fines Ranbaxy, others for blocking cheaper drugs, Economic Times reports
Subscribe for More Information | | | 07:44 EDT | | TEVA | Teva initiated with a Buy at Maxim
Target $56. | | | 06:11 EDT | | TEVA | Teva settles lawsuit, agrees to specify executive pay, Bloomberg reports
Subscribe for More Information | | | June 17, 2013 | | 13:20 EDT | | TEVA, ACT | Supreme Court rules generic drug makers can be sued over 'pay to delay'
Subscribe for More Information | | | 11:54 EDT |  | TEVA, ACT | Supreme Court ruling a modest negative for generics, says Leerink
Subscribe for More Information | | | 11:49 EDT | | ACT | U.S. Supreme Court reverses U.S. Court of Appeals decision in FTC vs. Actavis
Subscribe for More Information | | | 09:31 EDT | | TEVA | Teva acquires MicroDose Therapeutx
Subscribe for More Information | | | 07:25 EDT |  | TEVA, ACT | Leerink to host a conference
Subscribe for More Information | | | | June 14, 2013 | | 08:06 EDT | | TEVA | Teva says studies further define utility of Azilect in Parkinson’s treatment
Teva Pharmaceutical announced that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson’s Disease and Movement Disorders in Sydney, Australia, June 16-20, also known as the Movement Disorders Society. “The AZILECT abstract topics presented at MDS demonstrate our efforts to further clarify the clinical utility of rasagiline to prescribers and PD patients across various stages of the disease,” said Michael Hayden, MD, President of Global R&D and Chief Scientific Officer at Teva. | | | June 12, 2013 | | 08:28 EDT | | TEVA | Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix
Subscribe for More Information | | | 08:23 EDT | | TEVA | Teva, Active Biotech announces results of Phase IIa study of laquinimod
Subscribe for More Information | | | 08:09 EDT | | TEVA | Teva's Laquinimod for lupus reports positive Phase II results
Subscribe for More Information | | | 08:02 EDT | | TEVA | Pfizer wins $2.15B settlement from Teva and Sun for patent infringement
Subscribe for More Information | | | 07:08 EDT | | ACT, TEVA | Drugstores ready access changes to Plan B pill, WSJ reports
Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, reports the Wall Street Journal.Reference Link | | | 06:53 EDT | | ACT | Columbia Laboratories announces class action lawsuit against company dismissed
Subscribe for More Information | | | 06:05 EDT | | TEVA, ACT | On the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: The tectonic plates of the world economy are shifting, moving the yield on the 10-year Treasury to the highest level in more than a year and shaking financial markets. Now, some constants are being questioned in markets, triggering paroxysms in stocks, bonds, commodities and the currencies of emerging markets, the Wall Street Journal reports...Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, the Wall Street Journal reports...REUTERS: If currency turbulence in emerging markets becomes a full-scale investor flight, the Fed may have a new headache in deciding when to slow its dollar printing policy. The link between U.S. monetary policy and currency runs on the other side of the world could be tighter than many assume, Reuters reports...Toyota Motor (TM) said it’s unlikely to recapture its peak market share it held four years ago in the U.S. (GM, F), its biggest market, the latest sign the carmaker is shifting to improving quality from aggressively expanding sales, Reuters reports...BLOOMBERG: Exchange executives (NYX, NDAQ), long shielded from legal scrutiny in the U.S., have been put on notice that may be changing after federal regulators fined CBOE Holdings (CBOE) $6M for unprecedented lapses in supervision, Bloomberg reports...Borealis Infrastructure Management and its Kuwaiti-British partners abandoned their $8.3B bid for the U.K. water utility Severn Trent (SVTRY) as the offer deadline expired, Bloomberg reports. | | | June 11, 2013 | | 17:59 EDT | | ACT | Actavis, Medicines360 announce partnership
Medicines360, a non-profit pharmaceutical company, and Actavis, announced a partnership to support Medicines360’s mission to reduce cost as a barrier to accessing women’s birth control. The Medicines360 and Actavis partnership will make the IUD available in the U.S. commercially and at a very low price in U.S. public sector clinics. As part of this agreement, Actavis has licensed the U.S. commercial rights for the Medicines360 LNG20 Intrauterine Device, or IUD. Medicines360 retains rights to market the product in the U.S. public sector, including family planning clinics that provide services to low-income women. LNG20, originally developed by Uteron Pharma S.P.R.L. in Belgium, is designed to initially deliver 20 mcg of levonorgestrel per day for the indication of long term contraception, and is currently in Phase III clinical trials in the United States. Pending FDA approval, the LNG20 IUD could be launched in the U.S. as early as 2014. | | | 10:14 EDT | | ACT | Actavis acquires U.S. commercial rights for LNG20 IUD
Medicines360, a non-profit pharmaceutical company, and Actavis announced a partnership to support Medicines360’s mission to reduce cost as a barrier to accessing women’s birth control. The Medicines360 and Actavis partnership will make the IUD available in the U.S. commercially and at a very low price in U.S. public sector clinics. As part of this agreement, Actavis has licensed the U.S. commercial rights for the Medicines360 LNG20 Intrauterine Device. Medicines360 retains rights to market the product in the U.S. public sector, including family planning clinics that provide services to low-income women. LNG20 is currently in Phase III clinical trials in the United States. Pending U.S. Food and Drug Administration approval, the LNG20 IUD could be launched in the U.S. as early as 2014, the companies said. | | |
|
|
|
|
|
|
